Avodart Capsule, Liquid Filled
Product Images NDC 80725-712

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Avodart (NDC 80725-712). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Waylis Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dutasteride Structural Formula (Avodart Spl Image 01)

FDA Label Image

Figure 1. Aua-si Score* Change From Baseline (randomized, Double-blind, Placebo-controlled Studies Pooled) (Avodart Spl Image 02)

FDA Label Image

Figure 2. Percent Of Subjects Developing Acute Urinary Retention Over A 24-month Period (randomized, Double-blind, Placebo-controlled Studies Pooled) (Avodart Spl Image 03)

This text appears to be presenting data related to a clinical trial or study. It includes information about the number of events or outcomes observed in both a placebo group and a group receiving a medication called dutasteride, as well as the number of patients at risk in each group. The numbers seem to be related to a specific time period or duration of treatment, possibly 6 and 12 months. However, without a clearer context or additional information, it is difficult to provide a more specific description.*

FDA Label Image

Figure 3. Percent Of Subjects Having Surgery For Benign Prostatic Hyperplasia Over A 24-month Period (randomized, Double-blind, Placebo-controlled Studies Pooled) (Avodart Spl Image 04)

FDA Label Image

Figure 4. Prostate Volume Percent Change From Baseline (randomized, Double-blind, Placebo-controlled Studies Pooled) (Avodart Spl Image 05)

FDA Label Image

Figure 5. Qmax Change From Baseline (randomized, Double-blind, Placebo-controlled Studies Pooled) (Avodart Spl Image 06)

Not available.*

FDA Label Image

Figure 6. (Avodart Spl Image 07)

FDA Label Image

Figure 7. Q-max Change Ffrom Baseline Over A 24-month Period (randomized, Double-blind, Parallel Group Study [combat Study]) (Avodart Spl Image 08)

FDA Label Image

Avodart 0.5 mg 90 Count Label (Avodart Spl Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.